this subtyping is the basis of the h#n# designations of the influenza a viruses. with a few adaptations, propagation of influenza viruses in chicken eggs remains the primary means for growing virus for vaccine production and biomedical research (treanor, 2010). it is also not recommended for persons with asthma and children between 2 and 4 years of age with a history of asthma or wheezing episodes in the 12 months prior to vaccination (cdc, 2010b). the publication, described above, did not present evidence sufficient for the committee to conclude the vaccine may be a contributing cause of encephalitis after administration of an influenza vaccine. the publications described above did not present evidence sufficient for the committee to conclude the vaccine may be a contributing cause of encephalopathy after administration of an influenza vaccine. half of the study population overlapped the patients observed in the study by france et al. cases were matched to three controls (children who did not have the outcome of interest) on date of birth and gender; the index date for the controls was the date the event was observed in the matched case. the committee has a moderate degree of confidence in the epidemiologic evidence based on four studies with sufficient validity and precision to assess an association between influenza vaccine and seizures; these studies consistently report a null association. the symptoms described in the publications referenced above are consistent with those leading to a diagnosis of seizure. the committee reviewed one study to evaluate the risk of transverse myelitis after the administration of influenza vaccine. the authors concluded that influenza vaccination did not appear to be associated with an increased risk of optic neuritis in adults. these publications did not contribute to the weight of mechanistic evidence. no studies were identified in the literature for the committee to evaluate the risk of neuromyelitis optica (nmo) after the administration of influenza vaccine. the authors concluded that influenza vaccination does not appear to be associated with an increased risk of ms onset in adults. the committee assesses the mechanistic evidence regarding an association between influenza vaccine and onset of ms in adults as lacking. conclusion 6.8: the evidence is inadequate to accept or reject a causal relationship between influenza vaccine and onset of ms in adults. the committee identified three publications reporting the administration of an influenza vaccine to patients with ms. moriabadi et al. conclusion 6.9: the evidence is inadequate to accept or reject a causal relationship between influenza vaccine and relapse of ms in adults. (1982) conducted a cohort study in gbs patients and used the same methods as hurwitz et al. a total of 289 patients were hospitalized for onset of gbs at u.s. army medical treatment facilities from 1980 through 1988. the risk period was defined as cases of gbs occurring during november of 1980 to 1988, and the control period included cases reported in non-november months during these years. a total of 51 cases were observed in the risk period and 141 cases were observed in the control period. the date of influenza immunization was obtained from the medical record and the risk period was defined as 60 days prior to the gbs consultation (or assigned date in controls). the authors concluded that the risk of gbs after influenza vaccination was not significantly elevated compared to no vaccine during the 2005–2006, 2006–2007, and 2007–2008 seasons. in addition, strains of influenza targeted by the vaccine vary each year and associations with gbs also may vary. the publications described above did not present evidence sufficient for the committee to conclude the vaccine may be a contributing cause of gbs after administration of an influenza vaccine. no studies were identified in the literature for the committee to evaluate the risk of chronic inflammatory disseminated polyneuropathy (cidp) after the administration of influenza vaccine. evidence beyond a temporal relationship between administration of the vaccine and development of cidp after vaccination was not provided in any of the reports. a total of 2,128 patients were included in the analysis; they experienced 2,263 bell’s palsy episodes, and received 8,376 doses of influenza vaccine. no studies were identified in the literature for the committee to evaluate the risk of brachial neuritis after the administration of influenza vaccine. no studies were identified in the literature for the committee to evaluate the risk of small fiber neuropathy after the administration of influenza vaccine. between the 2002–2003 and 2006–2007 influenza seasons 91 of 146 patients developed a positive response to an influenza vaccine skin test. (2005) reviewed adverse events, reported to vaers, after administration of a live attenuated influenza vaccine during the 2003–2004 and 2004–2005 influenza seasons. the publications, described above, presented clinical evidence sufficient for the committee to conclude the vaccine was a contributing cause of anaphylaxis after administration of influenza vaccines. the committee reviewed eight studies to evaluate the risk of asthma or reactive airway disease episodes after tiv administration in children and adults with a prior diagnosis of asthma. (2003) conducted a self-controlled case-series study in 6,000 patients with asthma and 6,000 patients with chronic obstructive pulmonary disease (65 to 79 years of age) who were randomly selected from the gprd.
no differences in asthma symptoms were reported between the tiv and placebo groups within 7 days of injection. one study (rosenberg et al., 2009) was not considered in the weight of epidemiologic evidence because it provided data from a passive surveillance system and lacked an unvaccinated comparison population. the authors concluded that tiv does not increase the risk of asthma in children during the 14 days after vaccination. studies included in the weight of epidemiologic evidence for inactivated influenza vaccine and asthma exacerbation or reactive airway disease episodes in children and adults. the publication described above did not present evidence sufficient for the committee to conclude the vaccine may be a contributing cause of asthma exacerbation or reactive airway disease episodes in children and adults after administration of an inactivated influenza vaccine. there is a concern for the lack of simultaneous adjustment for age and history of asthma or reactive airway disease visits, which was discussed above in bergen et al. (2008) conducted a reanalysis of the study from piedra et al. the authors did not find an increased risk of asthma exacerbation or new onset asthma during the 0-to-14-day or 0-to-42-day risk period after laiv administration in the 18-month to 4-year age group during any of the 4 study years. in examining evidence for an association of asthma with tiv or laiv immunization, the committee addressed asthma or wheezing episodes in study populations with and without a prior diagnosis of asthma. studies included in the weight of epidemiologic evidence for live attenuated influenza vaccine and asthma exacerbation or reactive airway disease episodes in children younger than 5 years of age. one study (izurieta et al., 2005) was not considered in the weight of epidemiologic evidence because it provided data from a passive surveillance system and lacked an unvaccinated comparison population. (2008) conducted a reanalysis of the study from piedra et al. studies included in the weight of epidemiologic evidence for live attenuated influenza vaccine and asthma exacerbation or reactive airway disease episodes in persons 5 years of age or older. these publications did not contribute to the weight of mechanistic evidence. conclusion 6.18: the evidence is inadequate to accept or reject a causal relationship between laiv and asthma exacerbation or reactive airway disease episodes in persons 5 years of age or older. the studies considered in the epidemiologic evidence consist of one small rct comparing influenza vaccine and no vaccine in sle patients (williams et al., 1978) and three observational studies that include unvaccinated patients (abu-shakra et al., 2000; del porto et al., 2006; stojanovich, 2006). the epidemiologic evidence is insufficient or absent to assess an association between influenza vaccine and onset of sle. conclusion 6.19: the evidence is inadequate to accept or reject a causal relationship between influenza vaccine and onset or exacerbation of sle. disease relapse was assessed by reviewing the medical charts for new or increased disease activity and was attributed to influenza vaccination if the vaccine was administered within 1 year of the relapse. the epidemiologic evidence is insufficient or absent to assess an association between influenza vaccine and onset of vasculitis. no studies were identified in the literature for the committee to evaluate the risk of polyarteritis nodosa (pan) after the administration of influenza vaccine. the epidemiologic evidence is insufficient or absent to assess an association between influenza vaccine and onset or exacerbation of arthropathy. a total of 19,063 patients with a validated date of a first stroke and influenza vaccination were included in the analysis. a total of 20,486 patients with a validated date of a first myocardial infarction and influenza vaccination were included in the analysis. conclusion 6.24: the evidence is inadequate to accept or reject a causal relationship between influenza vaccine and myocardial infarction.4 no studies were identified in the literature for the committee to evaluate the risk of fibromyalgia after the administration of influenza vaccine. the committee has a moderate degree of confidence in the epidemiologic evidence based on a single study with sufficient validity and precision to assess an association between influenza vaccine and all-cause mortality; this study reports a decreased risk. (2003), and patients who had ors following influenza vaccination during the 2000–2001 season were included in skowronski et al. patients were eligible if they had ors after receiving the 2000–2001 influenza vaccine and were not revaccinated (group a), had ors after receiving the 2000–2001 influenza vaccine and were revaccinated in 2001–2002 (group b), or had a first occurrence of ors after receiving the 2001–2002 influenza vaccine (group c). (2006) did not observe an increased frequency of conjunctivitis symptoms following influenza vaccine in the united states. two publications did not provide evidence beyond temporality and therefore did not contribute to the weight of mechanistic evidence (skowronski et al., 2003b,c). a total of 1,074 children were vaccinated during the 2000–2001 influenza season. the committee does not include in this review any of the studies of the 1976–1977 swine influenza vaccine and its relationship to gbs. studies assessed as having very serious limitations were not considered in the weight of epidemiologic evidence. studies assessed as having very serious limitations were not considered in the weight of epidemiologic evidence. studies assessed as having very serious limitations were not considered in the weight of epidemiologic evidence.
concerns about side effects, allergic reactions, and a rare immune disorder associated with the flu shot are keeping some people from getting vaccinated. while the flu and the common cold have some symptoms in common, the flu can knock people flat for a few days to as long as two weeks, and it can also have far more dire consequences. indeed, reduced population immunity (due to a lack of exposure to the flu last year) could result in an early, and possibly severe, flu season, cautions the cdc.
people with asthma, heart disease, diabetes, and a number of other chronic health conditions are at a higher risk of developing serious flu complications that can result in hospitalization or even death, per the cdc. “but it can be a paralyzing disease, so it is certainly something severe enough to mention.” the mayo clinic notes that most people recover from gbs, and several treatments can ease symptoms and reduce the duration of the illness. scientists are developing a new kind of flu vaccine, inspired by the highly effective mrna covid-19 vaccines from pfizer and moderna.
have you had a reaction following a vaccination? contact your healthcare provider. report an adverse event using the vaers online form or the downloadable pdf more information on reporting an adverse event to vaersexternal icon. if you need further assistance, please email info@vaers.org or call 1-800-822-7967. top of besides the injection site reactions, headache (101), myalgia (90) and pyrexia (86) were the most reported aefi. notably, there were 26 reports of extensive, flu vaccine 2021 side effects, flu vaccine 2021 side effects, reasons not to get the flu shot, serious side effects of flu jab, how to relieve flu shot side effects.
afterward, the reaction should be reported to the vaccine adverse event reporting system (vaers). your doctor might file this report, or you can do it yourself through the vaers website , or by calling 1-800-822-7967. the most common complications include primary influenza viral pneumonia, secondary bacterial pneumonia, and the exacerbation of chronic pulmonary and the flu shot can make your arm sore and cause a low-grade fever. learn about other potential (but very rare) risks, like guillain-barré influenza vaccinations are known to be temporally associated with common minor adverse events of interest (aeis) as well as distinct adverse, what to avoid after flu shot, flu shot side effects – mayo clinic, 2020 flu shot side effects for seniors, flu jab side effects a week later, flu vaccine side effects 2021 diarrhea, adverse event reporting form, flu shot side effects fatigue, cdc covid vaccine side effects, adverse events database, vaers id 1074247.
When you try to get related information on flu shot adverse reaction reporting, you may look for related areas. flu vaccine 2021 side effects, reasons not to get the flu shot, serious side effects of flu jab, how to relieve flu shot side effects, what to avoid after flu shot, flu shot side effects – mayo clinic, 2020 flu shot side effects for seniors, flu jab side effects a week later, flu vaccine side effects 2021 diarrhea, adverse event reporting form, flu shot side effects fatigue, cdc covid vaccine side effects, adverse events database, vaers id 1074247.